Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 10, 2025, titled "Glenmark Secures China Approval For RYALTRIS®, Reinforcing Respiratory Innovation Leadership".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals has received regulatory approval from China for RYALTRIS®, its fixed-dose combination nasal spray used to treat allergic rhinitis. RYALTRIS® is an established product in Glenmark's global respiratory portfolio, already marketed in several countries. The China approval opens access to one of the world's largest pharmaceutical markets, significantly expanding the drug's commercial reach. This milestone strengthens Glenmark's positioning as a respiratory innovation specialist and supports its long-term growth strategy in emerging and regulated markets.
Positive for shareholders — entry into the China market adds a large new revenue stream for an existing product and validates Glenmark's respiratory franchise. Likely to be viewed as a growth catalyst by the market.